Claims

1. A compound according to Formula **I**



(Formula **I**)

Meta or para

or a pharmaceutically acceptable salt thereof wherein:

- A_{11} – A_{14} are N or CR_{11}, CR_{12}, CR_{13}, CR_{14}, respectively, with the proviso that no more than two of the four positions A in A_{11}-A_{14} can be simultaneously N;
- A_6, A_7, A_8, A_9,A_{10} are N or CR_6, CR_7, CR_8, CR_9, CR_{10}, respectively, with the proviso that at least one but no more than two of the five positions A in A_6, A_7, A_8, A_9, A_{10} is N;
- R_1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;
- R_2 and R_3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R_2 and R_3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F;
- R_4 is H or C(1-6)alkyl;

- R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkoxy or cyano;
- the sulfonyl group with R_1 is represented by one of R_7, R_8 or R_9;
- the remaining R_6-R_{14} are independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F; and
- R_{15} is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkoxy or cyano;
- and R_{16} is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkyl, C(1-2)alkoxy or cyano.

2. The compound according to claim 1 wherein :

- A_{11} – A_{14} are N or CR_{11}, CR_{12}, CR_{13}, CR_{14}, respectively, with the proviso that no more than two of the four positions A in A_{11}-A_{14} can be simultaneously N;
- A_6, A_7, A_9, A_{10} are N or CR_6, CR_7, CR_9, CR_{10}, respectively, with the proviso that at least one but no more than two of the four positions A in A_6, A_7, A_9, A_{10} is N;
- A_8 is CR_8;
- R_1 is C(3-6)cycloalkylC(1-3)alkyl or (di)C(3-6)cycloalkylamino with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;
- R_2 and R_3 are independently H;
- R_4 is H;
- R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkoxy or cyano;

- the sulfonyl group with R_1 is represented by R_8;
- the remaining R_6-R_{14} are independently H, halogen, C(1-3)alkoxy or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F or hydroxy; and
- R_{15} is C(1-6)alkyl or C(3-6)cycloalkyl, all groups optionally substituted with one or more F, C(1-2)alkoxy or cyano;
- and R_{16} is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkyl, C(1-2)alkoxy or cyano.

3. The compound according to any one of claim 1 or 2 wherein :
   - A_{11} – A_{14} are respectively CR_{11}, CR_{12}, CR_{13}, CR_{14};
   - A_6, A_7, A_9, A_{10} are N or CR_6, CR_7, CR_9, CR_{10}, respectively, with the proviso that at least one but no more than two of the four positions A in A_6, A_7, A_9, A_{10} is N;
   - A_8 is CR_8;
   - R_1 is C(3-6)cycloalkylC(1-3)alkyl, all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;
   - R_2 and R_3 are independently H;
   - R_4 is H;
   - R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl or C(2-5)heterocycloalkylC(1-3)alkyl;
   - the sulfonyl group with R_1 is represented by R_8;
   - the remaining R_6-R_{14} are independently H, halogen, C(1-3)alkoxy or C(1-6)alkyl, all carbon atoms of alkyl groups optionally substituted with one hydroxy;
   - R_{15} is C(1-6)alkyl or C(3-6)cycloalkyl, all carbon atoms of the alkyl groups optionally substituted with one or more F;
   - and R16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl or C(6-10)aryl, all carbon atoms of the alkyl groups optionally substituted with one or more F.

4. The compound according to any one of claim 1 or 2 wherein :
   - A_{11} or A_{14} is N, the remaining position A being CR_{11} or CR_{14};
   - A_{12} and A_{13} are respectively CR_{12} and CR_{13};

- A_6, A_7, A_9, A_{10} are N or CR_6, CR_7, CR_9, CR_{10}, respectively, with the proviso that at least one but no more than two of the four positions A in A_6, A_7, A_9, A_{10} is N;
- A_8 is CR_8;
- R_1 is C(3-6)cycloalkylC(1-3)alkyl;
- R_2 and R_3 are independently H;
- R_4 is H;
- R_5 is H;
- the sulfonyl group with R_1 is represented by R_8;
- the remaining R_6-R_{14} are independently H;
- R_{15} is C(1-6)alkyl, all carbon atoms of alkyl groups optionally substituted with one or more F;
- and R_{16} is C(1-6)alkyl, all carbon atoms of alkyl groups optionally substituted with one or more F.

5. The compound as defined in claim 1 which is selected from the group of :
2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[3-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[3-fluoro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

N-[3-chloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[3-methoxy-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[2-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[2-fluoro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[2-methoxy-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-pyridyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[1-hydroxy-1-(trifluoromethyl)butyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[1-hydroxy-3-methyl-1-(trifluoromethyl)butyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[1-hydroxy-4-methyl-1-(trifluoromethyl)pentyl]phenyl]acetamide;

N-[4-(1-cyclopentyl-2,2,2-trifluoro-1-hydroxy-ethyl)phenyl]-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]acetamide;

N-[4-[1-(cyclopentylmethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]acetamide;

N-[4-[1-(cyclohexylmethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[5-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)-2-pyridyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[dicyclopropyl(hydroxy)methyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[1-hydroxy-1-(trifluoromethyl)propyl]phenyl]acetamide (racemate);

(-)-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide (levogyre enantiomer); (+)-2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide (dextrogyre enantiomer);

2-[6-[(2-methylcyclopropyl)methylsulfonyl]-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-[(2,2-difluorocyclopropyl)methylsulfonyl]-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide (racemate);

(+)-2-[6-[(2,2-difluorocyclopropyl)methylsulfonyl]-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide (dextrogyre enantiomer);

(-)-2-[6-[(2,2-difluorocyclopropyl)methylsulfonyl]-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide (levogyre enantiomer);

2-[6-(cyclopropylmethylsulfonyl)-4-methyl-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-2-methyl-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-5-methyl-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-(oxetan-3-ylmethoxy)-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-(2-methoxyethoxy)-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)-3-pyridyl]-N-[4-[2,2,2-trifluoro-1-(2-hydroxyethoxy)-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[4-[2,2,2-trifluoro-1-isopropoxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[3-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl];

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[3-fluoro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[4-[dicyclopropyl(hydroxy)methyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)-2-pyridyl]-N-[4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)pyrimidin-2-yl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[5-(cyclopropylmethylsulfonyl)pyrazin-2-yl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[6-(cyclopropylmethylsulfonyl)pyridazin-3-yl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide;

2-[2-(cyclopropylmethylsulfonyl)pyrimidin-5-yl]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]acetamide.

6. Medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof.

7. Compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in therapy.

8. Pharmaceutical composition which comprises a compound of Formula I according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

9. Pharmaceutical composition according to claim 8, which further comprises at least one additional therapeutically active agent.

10. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn’s disease or multiple sclerosis.

11. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of osteoarthritis or asthma.

12. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of mucosal leishmaniasis.

13. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of Kawaski disease or Hashimoto’s thyroiditis.

14. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of RORγ-mediated cancer, RORγ-mediated autoimmune diseases or RORγ-mediated respiratory diseases.